Wolverine Asset Management LLC Buys New Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Wolverine Asset Management LLC bought a new stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 97,400 shares of the biopharmaceutical company’s stock, valued at approximately $178,000.

Several other hedge funds have also modified their holdings of the stock. BNP Paribas Financial Markets increased its holdings in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $71,000. MetLife Investment Management LLC increased its holdings in Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 8,546 shares during the last quarter. Atom Investors LP purchased a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $103,000. Finally, Green Alpha Advisors LLC increased its holdings in Inovio Pharmaceuticals by 103.2% during the 4th quarter. Green Alpha Advisors LLC now owns 65,446 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 33,232 shares during the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

INO has been the topic of several analyst reports. Oppenheimer dropped their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. HC Wainwright lowered their price target on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a report on Monday, January 13th. Finally, Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.40.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $2.02 on Tuesday. Inovio Pharmaceuticals, Inc. has a 12-month low of $1.74 and a 12-month high of $14.75. The business has a 50 day simple moving average of $2.01 and a 200 day simple moving average of $4.41.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.